Chemotherapy
Clinical Reports
Single Dose Kinetics of Mefloquine in ManPlasma Levels of the Unchanged Drug and of One of Its Metabolites aBiological Pharmaceutical Research Department, F. Hoffmann-La Roche & Co. Ltd., Basle. Switzerland; bClinical Unit, Hoffmann-La Roche Ltd., Grenzach-Wyhlen, FRG; cUniversity Centre of Health Sciences, Libreville, Gabon; dWHO Tropical Disease Research Centre, Ndola Central Hospital, Ndola, Zambia; eDépartement de Parasitologie et Médecine Tropicale, Hôpital Pitlé-Salpêtrière, Paris, France
|
|
Log in to MyKarger to check if you already have access to this content.
KAB
Buy a Karger Article Bundle (KAB) and profit from a discount!
If you would like to redeem your KAB credit, please log in.
Save over 20% compared to the individual article price.
Article / Publication Details
Published online: September 08, 2009
Issue release date: 1982
Number of Print Pages: 15
Number of Figures: 0
Number of Tables: 0
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Abstract
Oral single dose kinetics of mefloquine was investigated in 16 male volunteers, 3 Caucasians and 13 African natives. Unchanged mefloquine (= M) and one of its metabolites (= MM) were measured in the plasma. The apparent half-life of absorption of M ranged from 0.36 to 2.0 h, its terminal half-life of elimination from 15 to 33 days. Assuming complete systemic availability, an apparent volume of distribution of 14–29 liters kg-1 and a total clearance of 18–39 ml min-1 were derived. MM given orally to mice or rats showed at equal dose the same tolerance as mefloquine. Following oral administration of M to man, plasma levels of MM surpassed those of M, resulting in a 2.4–5.1 larger AUC. However, because of its much smaller apparent volume of distribution, MM may be anticipated to represent only a small percentage of the dose and therefore to contribute only to a minor extent towards the unwanted side effects of the drug.
© 1982 S. Karger AG, Basel
Related Articles:
Article / Publication Details
Published online: September 08, 2009
Issue release date: 1982
Number of Print Pages: 15
Number of Figures: 0
Number of Tables: 0
ISSN: 0009-3157 (Print)
eISSN: 1421-9794 (Online)
For additional information: https://www.karger.com/CHE
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.

Get Permission